Novel Therapies for Treatment of Food Allergy

Sultan Albuhairi; Rima Rachid

doi:10.1016/j.iac.2019.09.007

Novel Therapies for Treatment of Food Allergy

Immunol Allergy Clin North Am. 2020 Feb;40(1):175-186. doi: 10.1016/j.iac.2019.09.007.

Authors

Sultan Albuhairi¹, Rima Rachid²

Affiliations

¹ Department of Pediatrics, College of Medicine, Majmaah University, PO Box 66, Majmaah 11952, Saudi Arabia.
² Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: rima.rachid@childrens.harvard.edu.

PMID: 31761117
DOI: 10.1016/j.iac.2019.09.007

Abstract

Food allergy prevalence has increased over the past 2 decades and is estimated to affect 8% of children and 4% to 10% of adults. There is an unmet need to evaluate new therapeutic modalities that may decrease the risk of food-induced anaphylaxis and improve patients' quality of life. Oral, epicutaneous, and sublingual food immunotherapies have different safety and efficacy profiles, and their long-term outcome and applicability are unclear. Food allergy trials are currently evaluating different biologics (given as monotherapy or adjunct to immunotherapy), modified food proteins, DNA vaccines, and fecal microbiota transplantation.

Keywords: Biologics; Dupilumab; Fecal microbiota transplantation; Food allergy; Microbiome; Novel therapies; Omalizumab.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / therapeutic use
Biological Therapy / trends*
Fecal Microbiota Transplantation
Feces / microbiology*
Food Hypersensitivity / therapy*
Humans
Microbiota / immunology*
Omalizumab / therapeutic use
Vaccines, DNA / immunology*

Substances

Antibodies, Monoclonal, Humanized
Vaccines, DNA
Omalizumab
dupilumab